Potential predictive biomarkers for the dysfunction of β-cells in type 2 diabetes

Predictive Diagnostics and Personalized Treatment: Dream or Reality

Volumn , Issue , 2009, Pages 183-212

  Koehn, Jadranka ^a   Turhani, Dritan ^a   Krapfenbauer, Kurt ^b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Novartis Institutes for BioMedical Research Vienna   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79960047932     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (55)

1. Garvey WT, Olefsky JM, Griffin J, Hamman RF, Kolterman OG (1985) The effect of insulin treatment on insulin secretion and insulin action in type II diabetes mellitus. Diabetes, 34, 222-234.
2. Little RR, Rohlfing CL, Wiedmeyer HM, Myers GL, Sacks DB, Goldstein DE (2001) The national glycohemoglobin standardization program: a five-year progress report. Clin. Chem., 47, 1985-1992.
3. Landin-Olsson M, Nilsson KO, Lernmark A, Sundkvist G (1990) Islet cell antibodies and fasting C-peptide predict insulin requirement at diagnosis of diabetes mellitus. Diabetologia, 33, 561-568.
4. Meier C, Ladewig A, Keller U, Berger W (1997) [Clinical value of C-peptide determination]. Praxis, 86, 1289-1295.
5. Sacks DB, Bruns DE, Goldstein DE, Maclaren NK, McDonald JM, Parrott M (2002) Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Clin. Chem., 48, 436-472.
6. Koehn J, Fountoulakis M, Krapfenbauer K (2008) Multiple drug resistance associated with function of ABC-transporters in diabetes mellitus: molecular mechanism and clinical relevance. Infect. Disord. Drug Targets, 8, 109-118.
7. Sattar N, Wannamethee SG, Forouhi NG (2008) Novel biochemical risk factors for type 2 diabetes: pathogenic insights or prediction possibilities? Diabetologia, 51, 926-940.
8. Wannamethee SG, Shaper AG, Lennon L, Whincup PH (2005) Hepatic enzymes, the metabolic syndrome, and the risk of type 2 diabetes in older men. Diabetes Care, 28, 2913-2918.
9. Ding EL, Song Y, Malik VS, Liu S (2006) Sex differences of endogenous sex hormones and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA, 295, 1288-1299.
10. Smirnakis KV, Plati A, Wolf M, Thadhani R, Ecker JL (2007) Predicting gestational diabetes: choosing the optimal early serum marker. Am. J. Obstet. Gynecol., 196, 410.e1-410e7.
11. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM (2001) C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA, 286, 327-334.
12. Kaye TB, Guay AT, Simonson DC (1993) Non-insulin-dependent diabetes mellitus and elevated serum ferritin level. J. Diabetes Complicat., 7, 246-249.
13. Eshed I, Elis A, Lishner M (2001) Plasma ferritin and type 2 diabetes mellitus: a critical review. Endocr. Res., 27, 91-97.
14. Spranger J, Kroke A, Mohlig M, Bergmann MM, Ristow M, Boeing H, Pfeiffer AF (2003) Adiponectin and protection against type 2 diabetes mellitus. Lancet, 361, 226-228.
15. Vasseur F, Lepretre F, Lacquemant C, Froguel P (2003) The genetics of adiponectin. Curr. Diab. Rep., 3, 151-158.
16. Yamauchi T, Kamon J, Ito Y, Tsuchida A, Yokomizo T, Kita S, Sugiyama T, Miyagishi M, Hara K, Tsunoda M, Murakami K, Ohteki T, Uchida S, Takekawa S, Waki H, Tsuno NH, Shibata Y, Terauchi Y, Froguel P, Tobe K, Koyasu S, Taira K, Kitamura T, Shimizu T, Nagai R, Kadowaki T (2003) Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature, 423, 762-769.
17. Schmidt MI, Duncan BB, Vigo A, Pankow JS, Couper D, Ballantyne CM, Hoogeveen RC, Heiss G (2006) Leptin and incident type 2 diabetes: risk or protection? Diabetologia, 49, 2086-2096.
18. Festa A, D'Agostino R, Jr., Tracy RP, Haffner SM (2002) Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes, 51, 1131-1137.
19. Eliasson MC, Jansson JH, Lindahl B, Stegmayr B (2003) High levels of tissue plasminogen activator (tPA) antigen precede the development of type 2 diabetes in a longitudinal population study. The Northern Sweden MONICA study. Cardiovasc. Diabetol., 2, 19.
20. Wannamethee SG, Sattar N, Rumley A, Whincup PH, Lennon L, Lowe GD (2008) Tissue plasminogen activator, von Willebrand factor, and risk of type 2 diabetes in older men. Diabetes Care, 31, 995-1000.
21. Meigs JB, O'Donnell C J, Tofler GH, Benjamin EJ, Fox CS, Lipinska I, Nathan DM, Sullivan LM, D'Agostino RB, Wilson PW (2006) Hemostatic markers of endothelial dysfunction and risk of incident type 2 diabetes: the Framingham Offspring Study. Diabetes, 55, 530-537.
22. Jacqueminet S, Briaud I, Rouault C, Reach G, Poitout V (2000) Inhibition of insulin gene expression by long-term exposure of pancreatic beta cells to palmitate is dependent on the presence of a stimulatory glucose concentration. Metabolism, 49, 532-536.
23. Donath MY, Gross DJ, Cerasi E, Kaiser N (1999) Hyperglycemia-induced beta-cell apoptosis in pancreatic islets of Psammomys obesus during development of diabetes. Diabetes, 48, 738-744.
24. Shafrir E, Ziv E, Mosthaf L (1999) Nutritionally induced insulin resistance and receptor defect leading to beta-cell failure in animal models. Ann. N. Y. Acad. Sci., 892, 223-246.
25. Anello M, Rabuazzo AM, Degano C, Caltabiano V, Patane G, Vigneri R, Purrello F (1996) Fast reversibility of glucose-induced desensitization in rat pancreatic islets. Evidence for an involvement of ionic fluxes. Diabetes, 45, 502-506.
26. Marshak S, Leibowitz G, Bertuzzi F, Socci C, Kaiser N, Gross DJ, Cerasi E, Melloul D (1999) Impaired beta-cell functions induced by chronic exposure of cultured human pancreatic islets to high glucose. Diabetes, 48, 1230-1236.
27. Busch AK, Cordery D, Denyer GS, Biden TJ (2002) Expression profiling of palmitate- and oleate-regulated genes provides novel insights into the effects of chronic lipid exposure on pancreatic beta-cell function. Diabetes, 51, 977-987.
28. Carlsson C, Borg LA, Welsh N (1999) Sodium palmitate induces partial mitochondrial uncoupling and reactive oxygen species in rat pancreatic islets in vitro. Endocrinology, 140, 3422-3428.
29. Shimabukuro M, Zhou YT, Levi M, Unger RH (1998) Fatty acid-induced beta cell apoptosis: a link between obesity and diabetes. Proc. Natl. Acad. Sci. U.S.A., 95, 2498-2502.
30. Mandrup-Poulsen T (2001) beta-cell apoptosis: stimuli and signaling. Diabetes, 50 Suppl 1, S58-63.
31. Asfari M, Janjic D, Meda P, Li G, Halban PA, Wollheim CB (1992) Establishment of 2-mercaptoethanol-dependent differentiated insulin-secreting cell lines. Endocrinology, 130, 167-178.
32. Miyazaki J, Araki K, Yamato E, Ikegami H, Asano T, Shibasaki Y, Oka Y, Yamamura K (1990) Establishment of a pancreatic beta cell line that retains glucose-inducible insulin secretion: special reference to expression of glucose transporter isoforms. Endocrinology, 127, 126-132.
33. Praz GA, Halban PA, Wollheim CB, Blondel B, Strauss AJ, Renold AE (1983) Regulation of immunoreactive-insulin release from a rat cell line (RINm5F). Biochem. J., 210, 345-352.
34. Karlsson K, Cairns N, Lubec G, Fountoulakis M (1999) Enrichment of human brain proteins by heparin chromatography. Electrophoresis, 20, 2970-2976.
35. Shin JH, Krapfenbauer K, Lubec G (2006) Large-scale identification of cytosolic mouse brain proteins by chromatographic prefractionation. Electrophoresis, 27, 2799-2813.
36. Conrad EH. Heparin-binding proteins. San Diego: Academic Press, Inc., 1998
37. Pollak D, Krapfenbauer K, Fountoulakis M, Peyrl A, Lubec G (2004) Expressional pattern of known and predicted signaling proteins in seven human cell lines. J. Chromatogr., 808, 185-208.
38. Shin JH, Krapfenbauer K, Lubec G (2005) Column chromatographic prefractionation leads to the detection of 543 different gene products in human fetal brain. Electrophoresis, 26, 2759-2778.
39. Cagney G, Park S, Chung C, Tong B, O'Dushlaine C, Shields DC, Emili A (2005) Human tissue profiling with multidimensional protein identification technology. J. Proteome Res., 4, 1757-1767.
40. Florens L, Washburn MP (2006) Proteomic analysis by multidimensional protein identification technology. Methods Mol. Biol., 328, 159-175.
41. Fountoulakis M, Juranville JF, Jiang L, Avila D, Roder D, Jakob P, Berndt P, Evers S, Langen H (2004) Depletion of the high-abundance plasma proteins. Amino Acids, 27, 249-259.
42. Lubec G, Krapfenbauer K, Fountoulakis M (2003) Proteomics in brain research: potentials and limitations. Prog. Neurobiol., 69, 193-211.
43. Fountoulakis M, Langen H (1997) Identification of proteins by matrix-assisted laser desorption ionization-mass spectrometry following in-gel digestion in low-salt, nonvolatile buffer and simplified peptide recovery. Anal. Biochem., 250, 153-156.
44. Peyrl A, Krapfenbauer K, Slavc I, Yang JW, Strobel T, Lubec G (2003) Protein profiles of medulloblastoma cell lines DAOY and D283: identification of tumor-related proteins and principles. Proteomics, 3, 1781-1800.
45. Langen H, Roder D, Juranville JF, Fountoulakis M (1997) Effect of protein application mode and acrylamide concentration on the resolution of protein spots separated by two-dimensional gel electrophoresis. Electrophoresis, 18, 2085-2090.
46. Rockwood AL, Haimi P (2006) Efficient calculation of accurate masses of isotopic peaks. J. Am. Soc. Mass Spectrom., 17, 415-419.
47. DeFronzo RA (1997) Pathogenesis of type 2 diabetes: metabolic and molecular implications for identifying diabetes genes. Diabetes Rev., 5, 177-269.
48. Golubnitschaja O, Flammer J (2007) What are the biomarkers for glaucoma? Surv. Ophthalmol., 52 Suppl 2, S155-S161.
49. Golubnitschaja O, Yeghiazaryan K, Wunderlich K, Schild H, Flammer J (2007) Disease proteomics reveals altered basic gene expression regulation in leukocytes of Normal-Tension and Primary Open-Angle glaucoma patients. Proteomics Clin. Appl., 1, 1316-1323.
50. Krapfenbauer K, Fountoulakis M (in press 2008) Enrichment and Proteomic Analysis of Brain Proteins with Signaling Function by Heparin Chromatography. Methods Mol. Biol.
51. Clark A (1989) Islet amyloid and type 2 diabetes. Diabet. Med., 6, 561-567.
52. Nishi M, Sanke T, Nagamatsu S, Bell GI, Steiner DF (1990) Islet amyloid polypeptide. A new beta cell secretory product related to islet amyloid deposits. J. Biol. Chem., 265, 4173-4176.
53. Westermark P, Wernstedt C, Wilander E, Hayden DW, O'Brien TD, Johnson KH (1987) Amyloid fibrils in human insulinoma and islets of Langerhans of the diabetic cat are derived from a neuropeptide-like protein also present in normal islet cells. Proc. Natl. Acad. Sci. U.S.A., 84, 3881-3885.
54. Ohsawa H, Kanatsuka A, Yamaguchi T, Makino H, Yoshida S (1989) Islet amyloid polypeptide inhibits glucose-stimulated insulin secretion from isolated rat pancreatic islets. Biochem. Biophys. Res. Commun., 160, 961-967.
55. Howard CF, Jr. (1986) Longitudinal studies on the development of diabetes in individual Macaca nigra. Diabetologia, 29, 301-306.